Novo Nordisk opens new research centre in Seattle
“Seattle is a biotech centre of excellence, and placing our inflammation research centre here allows us to attract top scientists and collaborate with high quality partners,” said Mads Krogsgaard Thomsen, Novo Nordisk’s chief science officer. “By investing in early stage research we hope to find the underlying causes for different inflammatory conditions and develop new treatments for these diseases.”
Novo Nordisk announced its plans to create a new research centre in Seattle in August 2008 and has assembled a highly skilled management team led by Don Foster, vice president of inflammation. It is planned that the centre will have a total of 60 employees by the end of 2010. Research activities in Seattle will complement continuing biopharmaceutical research activities in Novo Nordisk’s research sites in Måløv in Denmark and Beijing in China.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.